Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota

Clinical Transplantation

Volumn 25, Issue 5, 2011, Pages 705-713

  Wudhikarn, Kitsada ^a   Holman, C J ^a   Linan, M ^b   Blaes, A H ^c   Dunitz, J M ^a   Hertz, M E ^a   Peterson, B A ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Epstein Barr virus; Lung transplantation; Post transplant lymphoproliferative disorders

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR; VINCRISTINE;

ACUTE GRAFT REJECTION; ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; BONE MARROW DISEASE; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EISENMENGER COMPLEX; EPSTEIN BARR VIRUS INFECTION; FEBRILE NEUTROPENIA; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL HEMORRHAGE; GRAFT RECIPIENT; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LUNG GRAFT REJECTION; LUNG INFILTRATE; LUNG NODULE; LUNG TRANSPLANTATION; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDIASTINUM DISEASE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLASMACYTOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SENSORY NEUROPATHY; SMALL INTESTINE DISEASE; SYSTEMIC THERAPY; THORAX DISEASE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80054119759     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01332.x     Document Type: Article

References (59)

1. Doak PB, Montgomerie JZ, North JD et al. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968: 4: 746.
2. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005: 56: 155.
3. Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991: 10: 877.
4. Montone KT, Litzky LA, Wurster A et al. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996: 119: 544.
5. Aris RM, Maia DM, Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996: 154(6 Pt 1):1712.
6. Levine SM, Angel L, Anzueto A et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999: 116: 1273.
7. Angel LF, Cai TH, Sako EY et al. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000: 5: 26.
8. Paranjothi S, Yusen RD, Kraus MD et al. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001: 20: 1054.
9. Wigle DA, Chaparro C, Humar A et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001: 72: 1783.
10. Reams BD, McAdams HP, Howell DN et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003: 124: 1242.
11. Ramalingam P, Rybicki L, Smith MD et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002: 15: 647.
12. Gao SZ, Chaparro SV, Perlroth M et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003: 22: 505.
13. Stein S, Misleh J, Ahya V et al. Post-transplant lymphoproliferative disorder in adult lung transplant recipients: a report on twenty-seven patients. J Clin Oncol 2008: 26: (May 20 suppl; abstr 19521).
14. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002: 21: 297.
15. Snell GI, Boehler A, Glanville AR et al. Eleven years on: a clinical update of key areas of the 1996 lung allograft rejection working formulation. J Heart Lung Transplant 2007: 26: 423.
16. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996: 15(1 Pt 1): 1.
17. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982: 5: 649.
18. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971: 31: 1860.
19. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. Engl J Med 1993: 329: 987.
20. Luce JK, Gamble JF, Wilson HE et al. Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer 1971: 28: 306.
21. McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976: 38: 1484.
22. Lichtman SM, Niedzwiecki D, Barcos M et al. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. Ann Oncol 2000: 11: 1141.
23. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
24. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990: 323: 1723.
25. Walker RC, Paya CV, Marshall WF et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995: 14: 214.
26. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995: 20: 1346.
27. Cherikh WS, Kauffman HM, McBride MA et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289.
28. Knight JS, Tsodikov A, Cibrik DM et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009: 27: 3354.
29. Ghobrial IM, Habermann TM, Macon WR et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005: 79: 244.
30. Bakker NA, Van Imhoff GW, Verschuuren EA et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005: 19: 327.
31. Khedmat H, Taheri S. Early onset post-transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant 2009: 14: 74.
32. Hachem RR, Chakinala MM, Yusen RD et al. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation 2004: 77: 431.
33. Halkos ME, Miller JI, Mann KP et al. Thoracic presentations of posttransplant lymphoproliferative disorders. Chest 2004: 126: 2013.
34. Shitrit D, Shitrit AB, Dickman R et al. Gastrointestinal involvement of posttransplant lymphoproliferative disorder in lung transplant recipients: report of a case. Dis Colon Rectum 2005: 48: 2144.
35. Swerdlow SH, Campo E, Harris NL et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008.
36. Lucioni M, Capello D, Riboni R et al. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution. Transplantation 2006: 82: 1013.
37. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998: 82: 1978.
38. Borhani AA, Hosseinzadeh K, Almusa O et al. Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation. Radiographics 2009: 29: 981.
39. Blaes AH, Cioc AM, Froelich J et al. Positron emission tomography (PET) scanning in the setting of post-transplant lymphoproliferative disorders. Clin Transplant 2009: 23: 794.
40. Bianchi E, Pascual M, Nicod M et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 2008: 85: 707.
41. Marom EM, McAdams HP, Butnor KJ et al. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post-transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging 2004: 19: 74.
42. Buadi FK, Heyman MR, Gocke CD et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol 2007: 82: 208.
43. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005: 24: 671.
44. Cantarovich M, Barkun JS, Forbes RD et al. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 1998: 12: 109.
45. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007: 110: 1123.
46. Benkerrou M, Durandy A, Fischer A. Therapy for transplantrelated lymphoproliferative diseases. Hematol Oncol Clin North Am 1993: 7: 467.
47. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001: 71: 1076.
48. Swinnen LJ, LeBlanc M, Grogan TM et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplant lymphoproliferative disorder. Transplantation 2008: 86: 215.
49. Funch DP, Brady J, Ko HH et al. Methods and objectives of a large US multicenter case control study of posttransplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 2002: 159: 81.
50. Cook RC, Connors JM, Gascoyne RD et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999: 354: 1698.
51. Blaes AH, Peterson BA, Bartlett N et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005: 104: 1661.
52. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000: 11(Suppl 1): 113.
53. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006: 107: 3053.
54. González-Barca E, Domingo-Domenech E, Capote FJ et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007: 92: 1489.
55. Knoop C, Kentos A, Remmelink M et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant 2006: 20: 179.
56. Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007: 41: 1648.
57. Taylor AL, Bowles KM, Callaghan CJ et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006: 82: 375.
58. Trappe R, Riess H, Babel N et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007: 83: 912.
59. Trappe R, Choquet S, Oertel SHK et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD - moving forward to a first standard of care: results from a prospective international multicenter trial. Blood (ASH Annual Meeting Abstracts) 2009: 114: 100.